Personalis (NASDAQ:PSNL) Given Hold Rating at Needham & Company LLC

Posted by George Bondi on Jul 20th, 2026

Personalis (NASDAQ:PSNL – Get Free Report)‘s stock had its “hold” rating reissued by equities researchers at Needham & Company LLC in a report issued on Monday,Benzinga reports.

Other analysts have also issued reports about the stock. Morgan Stanley raised their price objective on shares of Personalis from $9.00 to $13.00 and gave the company an “equal weight” rating in a research note on Thursday, July 9th. BTIG Research cut their price target on shares of Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st. TD Cowen restated a “buy” rating on shares of Personalis in a report on Wednesday. Finally, Wall Street Zen cut Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.50.

Get Our Latest Report on PSNL

Personalis Trading Down 14.3%

Personalis stock traded down $2.21 during trading hours on Monday, hitting $13.18. 6,996,025 shares of the stock traded hands, compared to its average volume of 2,450,126. Personalis has a one year low of $3.84 and a one year high of $16.39. The firm’s 50-day moving average price is $10.94 and its two-hundred day moving average price is $8.91. The company has a market cap of $1.38 billion, a PE ratio of -12.95 and a beta of 2.24.

Personalis (NASDAQ:PSNL – Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). The business had revenue of $15.47 million for the quarter, compared to the consensus estimate of $14.48 million. Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. On average, sell-side analysts expect that Personalis will post -1.07 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Aaron Tachibana sold 4,982 shares of the firm’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $14.00, for a total transaction of $69,748.00. Following the completion of the transaction, the chief financial officer owned 198,833 shares in the company, valued at $2,783,662. This trade represents a 2.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of the company’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $15.08, for a total transaction of $1,508,000.00. Following the sale, the chief executive officer directly owned 235,986 shares in the company, valued at approximately $3,558,668.88. The trade was a 29.76% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 435,032 shares of company stock worth $5,599,929. 4.20% of the stock is owned by company insiders.

Institutional Trading of Personalis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada boosted its stake in shares of Personalis by 3.2% during the first quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock valued at $275,000 after purchasing an additional 2,395 shares during the period. Dynamic Technology Lab Private Ltd increased its holdings in shares of Personalis by 75.6% during the first quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company’s stock valued at $269,000 after acquiring an additional 33,044 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in Personalis by 55.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company’s stock worth $998,000 after acquiring an additional 101,706 shares during the period. Focus Partners Wealth acquired a new stake in shares of Personalis during the first quarter worth about $47,000. Finally, JPMorgan Chase & Co. boosted its position in Personalis by 505.6% in the second quarter. JPMorgan Chase & Co. now owns 29,491 shares of the company’s stock valued at $193,000 after buying an additional 24,621 shares during the last quarter. 61.91% of the stock is owned by hedge funds and other institutional investors.

About Personalis

(Get Free Report)

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.